Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer

NCT01573468 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT01573468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01573468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2012
Completion date
August 31, 2014
Enrollment
580 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric carcinoma